GlobeNewswire by notified

LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin

Share

· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data

CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the bcc Berlin.

Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBio's proprietary GeneRide(TM) platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific in vivo genome editing to deliver therapeutic genetic material without the use of vector-borne promoters or nucleases.

 "We are very excited to present proof-of-concept efficacy data in models of multiple genetic diseases and to demonstrate the breadth and the versatility of our GeneRideTM technology," said LogicBio President and CEO Fred Chereau. "We also feel fortunate developing our platform technology with world-renowned academic collaborators, enabling us to advance development candidates for early onset life-threatening diseases rapidly - from the benchtop into the clinic."

Due to the genomic editing feature, LogicBio's GeneRideTM technology has shown in preclinical studies that it can provide stable therapeutic levels of life-saving proteins after a single injection. It overcomes a major challenge of the conventional gene therapy in pediatric indications - dilution of therapeutic benefit due to the proliferation of cells in the growing tissue of a child. Thus, the GeneRide technology is uniquely suitable to treat many rare, early-onset and severe genetic diseases.

LogicBio presentations at the ESGCT Congress are as follows:

Oral Presentation

Title: GeneRide(TM): Therapeutic in vivo gene targeting without nucleases

Session: Gene Editing I

When: October 18, 2017, 2:40 p.m. CEST

Room: C01

Poster Presentation

Title: GeneRide(TM): Therapeutic in vivo gene targeting without nucleases

When: October 18, 2017, 6:50 p.m. CEST

Abstract Number: P129

A co-founder of LogicBio, Dr. Barzel is the president elect of the Israeli Society of Gene and Cell Therapy and a senior lecturer (associate professor) at the Department of Biochemistry at Tel Aviv University. Dr. Barzel has a research background in homologous recombination and gene targeting. He is a Summa cum Laude graduate of the Adi Lautman interdisciplinary program for outstanding students, and has earned his PhD in genetics from the laboratory of Professor Martin Kupiec at Tel Aviv University. Previously, Major Adi Barzel was a company commander in an armor brigade and in the officer's academy of the Israeli Defense Forces. He invented the GeneRide technology during his time as a postdoctoral fellow at the Kay Lab at Stanford Medicine, Stanford University. He has co-authored scientific papers in high-impact journals describing the GeneRide technology and its applications.

About LogicBio Therapeutics (www.logicbio.com; twitter: @logicbio)

A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children's Medical Research Institute in Sydney - the company's core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of vector-borne promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company's discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.


Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/21431f6d-93d7-4c5f-a5d1-1a51641c6b2f

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/81511cac-ee28-4f0e-add0-dcceb0ea0a5c

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/95980a56-cec5-4e55-850b-a5f2a1713159

Caroline Grossman
LogicBio Therapeutics, Inc.
(781) 771.5579
caroline@mirepoixllc.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LogicBio Therapeutics, Inc. via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye